Sarcoma in the young adult population: an international view.

Abstract:

:The outcomes in young adults aged 20-39 with sarcoma tend to be inferior compared to those in children and adolescents. There are differences in sarcoma histotype distribution with age, such that pediatric-type tumors predominate in the 20- to 25-year-old group while more adult-type sarcomas occur in those aged 35-39 years. Certain occupational exposures, co-infection with human herpes virus 8 (HHV-8) and human immunodeficiency virus (HIV), prior radiation exposure, and genetic syndromes are relevant risk factors. In many of the types of sarcoma encountered in 20 to 39 year olds, there are important biological differences compared to the tumors in younger patients that play a role in the outcomes for these patients. Increased research into these differences and incorporating our knowledge about them into treatments tailored towards this age group is necessary to overcome the relatively poor outcomes in young adult sarcoma patients.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Soliman H,Ferrari A,Thomas D

doi

10.1053/j.seminoncol.2009.03.006

subject

Has Abstract

pub_date

2009-06-01 00:00:00

pages

227-36

issue

3

eissn

0093-7754

issn

1532-8708

pii

S0093-7754(09)00043-8

journal_volume

36

pub_type

杂志文章,评审
  • In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence.

    abstract::Preliminary clinical studies demonstrated that 5' nor-anhydro-vinblastine, Navelbine (NVB) has a broader antitumor activity and fewer neurotoxic effects than vinblastine or vincristine. The tectal plate anlage of mouse embryos at the earliest stages of neuronal differentiation were used to analyze and compare the effe...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Binet S,Fellous A,Lataste H,Krikorian A,Couzinier JP,Meininger V

    更新日期:1989-04-01 00:00:00

  • Radiation Therapy Oncology Group (RTOG) studies in head and neck cancer.

    abstract::Since its foundation in 1971, the RTOG has conducted a successful clinical research program in head and neck mucosal squamous cell carcinoma with 22 treatment protocols and one registry study which combined have accumulated data on over 5,500 patients. The RTOG was the first multicenter group to evaluate neoadjuvant c...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Marcial VA,Pajak TF,Kramer S,Davis LW,Stetz J,Laramore GE,Jacobs JR,Al-Sarraf M,Brady LW

    更新日期:1988-02-01 00:00:00

  • Psychosocial and sexual functioning of survivors of breast cancer.

    abstract::The literature documents that the majority of breast cancer survivors have adjusted well after their first 2 years since diagnosis. However, there is a subset of survivors reporting psychological distress, including depression and anxiety, involving approximately 30% by 4 years post-treatment, but widely ranging from ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.08.025

    authors: Kornblith AB,Ligibel J

    更新日期:2003-12-01 00:00:00

  • The Bayesian basket design for genomic variant-driven phase II trials.

    abstract::Basket clinical trials are a new category of early clinical trials in which a treatment is evaluated in a population of patients with tumors of various histologic types and primary sites selected for containing specific genomic abnormalities. The objective of such studies is generally to discover histologic types in w...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2016.01.002

    authors: Simon R,Geyer S,Subramanian J,Roychowdhury S

    更新日期:2016-02-01 00:00:00

  • Feasibility of amifostine administration in conjunction with high-dose rate brachytherapy.

    abstract::This ongoing study was initiated to determine the feasibility of administering amifostine (Ethyol, WR-2721; MedImmune, Inc, Gaithersburg, MD) with monomodal high-dose rate (mHDR) brachytherapy and to assess the tolerability and side effects of this combination. To date, 18 patients suitable for prostate implant brachy...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.11.010

    authors: Dziuk T,Senzer N

    更新日期:2003-12-01 00:00:00

  • Alternate dosing schedules for cancer chemopreventive agents.

    abstract::Pharmacologic interventions for cancer risk reduction involve the chronic administration of synthetic or natural agents to reduce or delay the occurrence of malignancy. Despite the strong evidence for a favorable risk-benefit ratio for a number of agents in several common malignancies such as breast and prostate cance...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.09.014

    authors: Lazzeroni M,DeCensi A

    更新日期:2016-02-01 00:00:00

  • Imaging of lung cancer: old and new.

    abstract::Lung cancer is the leading cause of cancer death in the United States. Lung cancer is frequently encountered by the radiologist, whether the lung cancer is detected on a chest radiograph obtained in a symptomatic patient, or is an incidental finding. The radiologic workup of pulmonary lesions suspected of being lung c...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Broderick LS,Tarver RD,Conces DJ Jr

    更新日期:1997-08-01 00:00:00

  • Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials.

    abstract::The efficacy and toxicity of cisplatin/etoposide and carboplatin/etoposide combinations along with thoracic irradiation were prospectively assessed in patients with small cell lung cancer. Both combinations were equally effective. However, the carboplatin/etoposide regimen caused significantly less nausea, vomiting, n...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Kosmidis PA,Samantas E,Fountzilas G,Pavlidis N,Apostolopoulou F,Skarlos D

    更新日期:1994-06-01 00:00:00

  • Combination fluorouracil, folinic acid, and interferon alfa-2a: an active regimen in advanced pancreatic carcinoma.

    abstract::Based on promising results with 5-FU/FA or 5-FU/IFN-alpha in colorectal cancer, a pilot study was initiated to evaluate the effects of the combination 5-FU/FA/interferon alfa (IFN-alpha) in patients with advanced pancreatic cancer. Patients received 9 million units (MU) IFN-alpha subcutaneously three times a week or 6...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Knuth A,Bernhard H,Klein O,Meyer zum Büschenfelde KH

    更新日期:1992-04-01 00:00:00

  • Measuring quality of life: an emerging science.

    abstract::Quality of life (QOL) variables are increasingly included as end points in cancer therapy trials, supplementing such traditional end points as survival time in evaluating the effects of cancer treatments. Consensus has been reached that a number of QOL components (symptom status and physical, emotional, role, and soci...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Moinpour CM

    更新日期:1994-10-01 00:00:00

  • Comparative metabolism of tamoxifen and DNA adduct formation and in vitro studies on genotoxicity.

    abstract::Tamoxifen has been demonstrated to be hepatocarcinogenic in some but not all strains of the laboratory rat and is not a carcinogen in the mouse. To resolve the question of whether tamoxifen is genotoxic in humans, many laboratories have studied its interspecies metabolism and its propensity to form DNA adducts. This r...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Tannenbaum SR

    更新日期:1997-02-01 00:00:00

  • Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.

    abstract::Modulation of the signaling pathways that are aberrant in cancer cells has the potential to provide an effective nontoxic approach to patient management in a broad range of cancers. This quest has taken a major leap forward with the demonstration that STI-571 (imatinib mesylate) induces clinical and molecular remissio...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.08.011

    authors: Mills GB,Kohn E,Lu Y,Eder A,Fang X,Wang H,Bast RC,Gray J,Jaffe R,Hortobagyi G

    更新日期:2003-10-01 00:00:00

  • Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates.

    abstract::Transport of folates and antifolates in most cells is mediated by the reduced folate carrier (RFCI), an anion exchanging concentrative process, which is opposed by independent exit pump(s) that are directly coupled to energy metabolism. The balance of these processes governs the free intracellular folate level that is...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Sierra EE,Goldman ID

    更新日期:1999-04-01 00:00:00

  • Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues.

    abstract::Gastrointestinal stromal tumor (GISTs) are the most common connective tissue malignancies of the gastrointestinal (GI) tract, with an incidence on the order of 10-13 per million people per year. Primary therapy is usually surgical, but the recurrence rate of large, so-called high-risk tumors, with a high mitotic rate,...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2009.06.002

    authors: Reichardt P,Hogendoorn PC,Tamborini E,Loda M,Gronchi A,Poveda A,Schöffski P

    更新日期:2009-08-01 00:00:00

  • Paclitaxel in the treatment of esophageal cancer.

    abstract::Since its introduction, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antitumor activity in epidermoid carcinomas and adenocarcinomas originating in the esophagus. Paclitaxel is the most active single agent available to treat metastatic esophageal cancer. Combinations of ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Weiner LM

    更新日期:1999-02-01 00:00:00

  • Cyclooxygenase-2 inhibitors in colorectal cancer.

    abstract::Cyclooxygenase (COX) enzyme-dependent arachidonic acid metabolites occupy key positions in important physiologic processes such as immunity, reproduction, and vascular integrity. Large retrospective and prospective population-based studies have shown that the use of both nonselective, nonsteroidal anti-inflammatory dr...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00120-9

    authors: Stoehlmacher J,Lenz HJ

    更新日期:2003-06-01 00:00:00

  • Moving disease biology from the laboratory to the clinic.

    abstract::To address the urgent need for novel therapies for multiple myeloma (MM), long-term research efforts have characterized the mechanisms whereby MM cells home to the bone marrow and adhere to bone marrow stromal cells and extracellular matrix proteins. Research also characterizes the functional sequelae of this binding ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.34072

    authors: Anderson KC

    更新日期:2002-12-01 00:00:00

  • Hepatic arterial chemotherapy in metastatic colorectal patients.

    abstract::Hepatic metastases are a major cause of morbidity and mortality for patients with colorectal cancer (CRC). The rationale for hepatic arterial chemotherapy has both an anatomical and pharmacological basis. Several randomized clinical studies of fluoropyrimidine showed higher response rates in all trials when the drug w...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Kemeny NE,Ron IG

    更新日期:1999-10-01 00:00:00

  • Intraperitoneal therapy in renal failure.

    abstract::As continuous ambulatory peritoneal dialysis becomes more popular, the science of catheter selection, insertion, and maintenance becomes increasingly necessary. The proper use of and possible complications associated with several currently used catheters are discussed. The pros and cons of single- and double-cuff cath...

    journal_title:Seminars in oncology

    pub_type: 历史文章,杂志文章

    doi:

    authors: Twardowski ZJ

    更新日期:1985-09-01 00:00:00

  • Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy.

    abstract::For four decades, 5-fluorouracil was the only option available for patients with metastatic colorectal cancer. It provided a response rate of 15% to 20%, with a median survival of approximately 1 year. In the past 5 years, remarkable progress has been made in colorectal cancer research with the approval of irinotecan ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.04.022

    authors: Varadhachary GR,Hoff PM

    更新日期:2005-12-01 00:00:00

  • Validation of the Concept of a Common Typical Time of Disease Duration for Hepatocellular Carcinoma Patients Using the Fisher Information Processing of Tumor Imaging Results Combined With Network Phenotyping Strategy Quantification of Individual Patient C

    abstract::A primary goal of current clinical cancer research is the identification of prognostic tumor subtypes. It is increasingly clear that tumor growth depends on both internal tumor factors, and factors that are external to the tumor, such as microenvironment. We recently showed that parameter values alone are less importa...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2015.05.004

    authors: Pančoška P,Skála L,Nešetřil J,Carr BI

    更新日期:2015-08-01 00:00:00

  • The role of bone marrow transplantation in the non-Hodgkin's lymphomas.

    abstract::In a significant fraction of patients with NHL, disease develops that is resistant to conventional chemotherapy. Experience using high-dose chemotherapy, with or without TBI, and BMT is expanding. Remissions can be achieved in many patients with refractory NHL in particular those patients with tumors that are still ch...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Williams SF

    更新日期:1990-02-01 00:00:00

  • Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.

    abstract::The discovery of the HER2/neu proto-oncogene and its role in the pathogenesis of breast cancer tumors, and the development of the anti-HER2 monoclonal antibody, trastuzumab (Herceptin; Genentech, South San Francisco, CA), directed against the HER2 receptor represent major milestones in the research developments in bre...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90188-5

    authors: Slamon D,Pegram M

    更新日期:2001-02-01 00:00:00

  • How are bisphosphonates used today in breast cancer clinical practice?

    abstract::In the United States there are approximately 100,000 women living with metastatic breast cancer. Bone is the most common site of breast cancer metastases and it is estimated that up to 85% of patients dying from this disease have developed osseous involvement. Skeletal metastases are often associated with dangerous an...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2001.25445

    authors: Van Poznak C

    更新日期:2001-08-01 00:00:00

  • Reirradiation of recurrent head and neck cancers with curative intent.

    abstract::In patients with recurrent, previously irradiated head and neck cancer, the traditional therapy of palliative single- or multi-agent chemotherapy yields a 30% to 40% response rate with median survival durations of 8 to 10 months. However, long-term survival is rarely observed. Reirradiation with or without concurrent ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.09.003

    authors: Chmura SJ,Milano MT,Haraf DJ

    更新日期:2004-12-01 00:00:00

  • Improving patient care through molecular diagnostics.

    abstract::Traditional cancer diagnostic techniques include assessment of histologic appearance, identification of specific tumor subtypes, tumor grading, assessment of lymph node status, and presence of metastasis. These are useful for initial evaluation, but are limited in their ability to predict response to treatment and/or ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.07.017

    authors: Perez EA,Pusztai L,Van de Vijver M

    更新日期:2004-10-01 00:00:00

  • Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer.

    abstract::The majority of patients with advanced prostatic cancer respond either to castration or estrogen therapy. In an attempt to identify an alternative hormonal therapy, 25 symptomatic stage D prostate cancer patients were treated with megestrol acetate as initial hormonal therapy. Thirty-three patients were evaluable for ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Bonomi P,Pessis D,Bunting N,Block M,Anderson K,Wolter J,Rossof A,Slayton R,Harris J

    更新日期:1985-03-01 00:00:00

  • Infections in allogeneic bone marrow transplant recipients.

    abstract::Remarkable strides have been made in the management of infectious complications after bone marrow transplantation. Improved understanding of patterns of infection, the introduction of new antimicrobials, the advent of cytokines to enhance immune recovery, the development of better strategies to control graft-versus-ho...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Wingard JR

    更新日期:1993-10-01 00:00:00

  • The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.

    abstract::For patients whose breast cancers are not responsive to endocrine therapy, there are a large number of cytotoxic drugs that will induce a response. In spite of the introduction of new, very active drugs such as the taxanes, vinorelbine, capecitabine, gemcitabine, and trastuzumab, the anthracyclines are still as active...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.09.018

    authors: Robert NJ,Vogel CL,Henderson IC,Sparano JA,Moore MR,Silverman P,Overmoyer BA,Shapiro CL,Park JW,Colbern GT,Winer EP,Gabizon AA

    更新日期:2004-12-01 00:00:00

  • Pharmacogenetics in esophageal cancer.

    abstract::The current oncology practice of treating cancer with aggressive doses of radiation and chemotherapy is potentially disastrous, as response and side effects vary depending on several factors including pharmacogenetics. This study is the first to evaluate esophageal cancer treatment with a pharmacogenetic paradigm and ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2005.04.031

    authors: Wu X,Lu C,Chiang SS,Ajani JA

    更新日期:2005-12-01 00:00:00